Brief Title
Practicability and Acceptability of Stylomax® in Children
Official Title
Usability and Acceptability of Stylomax® in Growth Hormone Deficient Children.
Brief Summary
Primary objective: to evaluate the practicability and acceptability of STYLOMAX®, a new injection device for MAXOMAT®, in children, for 1 year.
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
practicability/acceptability of the Stylomax pen
Secondary Outcome
tolerability : pain (evaluation on pain scale)
Condition
Growth Hormone Deficiency
Intervention
somatropine
Study Arms / Comparison Groups
somatropine
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
12
Start Date
June 2003
Primary Completion Date
December 2005
Eligibility Criteria
Inclusion Criteria: - Children over 3 years of age with growth hormone deficiency, requiring treatment with MAXOMAT® according to the criteria of the MA. Exclusion Criteria: - The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Gender
All
Ages
3 Years - 18 Years
Accepts Healthy Volunteers
No
Contacts
Marie SEBILLE, Dr, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT00476385
Organization ID
L_8912
Study Sponsor
Sanofi
Study Sponsor
Marie SEBILLE, Dr, Study Director, Sanofi
Verification Date
February 2009